Before using the medication, verify the pharmacy name on your label, the active ingredient, concentration, beyond-use date, storage instructions, and the number of units that correspond to your prescribed dose
Food and Drug Administration (FDA) has approved Ozempic (semaglutide) as the first and only GLP-1 receptor agonist (GLP-1 RA) specifically indicated to reduce the risk of worsening kidney disease, kidney failure, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease (CKD)
For patients with diabetes, persistent sugar cravings accompanied by elevated blood glucose readings may indicate inadequate glycemic control requiring treatment intensification
Transparent Pricing medication costs consultation fees refill policies support services shipping fees Ongoing Support The best programs provide continued support throughout the patient journey rather than only issuing prescriptions
Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis
